⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31252469 | 0.75 | — | — | |
| Ethylene SCHEMBL27676317 | 0.71 | TSHR (0.31) | — | |
| Ethylene SCHEMBL2428158 | 0.71 | — | — | |
| Ethylene SCHEMBL15771259 | 0.71 | TSHR (0.31) | — | |
| Ethylene SCHEMBL29032527 | 0.71 | TSHR (0.31) | — | |
| SCHEMBL28311884 | 0.71 | — | — | |
| SCHEMBL5634458 | 0.71 | — | — | |
| SCHEMBL251442 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL1154 | 0.71 | — | — | |
| Acetonitrile SCHEMBL4300315 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172858-B2 | Combination pharmaceutical compositions and uses thereof | INTELLIKINE LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-9669032-B2 | Enhanced treatment regimens using mTOR inhibitors | INTELLIKINE LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | INTELLIKINE LLC | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| US-9295673-B2 | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof | INTELLIKINE LLC (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160038497-A1 | Enhanced Treatment Regimens Using mTOR Inhibitors | FAETH THERAPEUTICS, INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2968340-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | Intellikine, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130209543-A1 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE LLC (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013078440-A2 | ENHANCED TREATMENT REGIMENS USING MTOR INHIBITORS | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013070976-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012151562-A1 | COMBINATION PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | INTELLIKINE, LLC (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| EP-2252293-A2 | KINASE INHIBITORS AND METHODS OF USE | Intellikine, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009114870-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |